J Insur Med. 2025 Jul 1;52(1):3-5. doi: 10.17849/insm-52-1-3-5.1.
ABSTRACT
OBJECTIVE.—: To analyze a published study on all-cause mortality between psoriatic arthritis and matched population comparator-subjects to derive comparative mortality statistics applicable to life insurance underwriting.
METHOD.—: The pixel method was employed for extracting cumulative survivals. It was chosen for its capability to extract data from published graphs despite potential precision and reliability limitations.
RESULTS.—: The mortality analysis indicated an increase in mortality starting in year 4, aligning with the Table rating for Psoriatic arthritis. Pharmacological treatment data from the study revealed only 28% were on advanced therapies such as targeted synthetic or biologic DMARDs. This low percentage suggests most of the cohort had milder PsA, as advanced treatments are generally reserved for moderate to severe psoriatic arthritis. The distribution of treatment regimens provides essential insights into disease severity and its implications for mortality assessment.
CONCLUSION.—: The comparative mortality findings correspond to Table rating for psoriatic arthritis. This finding underscores the importance of understanding treatment profiles and disease severity in life insurance underwriting to accurately assess risk.
PMID:40047113 | DOI:10.17849/insm-52-1-3-5.1
